INmune Bio Shares Double after Reporting Positive Phase 1b Alzheimer's Trial Data: https://t.co/oawJnEFjUy

Its Phase 1b study of XPro1595 demonstrated decreased neuroinflammation in Alzheimer's patients.

$INMB #Alzheimers #healthcare #stocks @INmuneBio https://t.co/0ntqoRKd8S